ArticleMolecular and clinical oncology2016

Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer.

Mayura Nakano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.